C4 Therapeutics Inc at Stifel Targeted Oncology Days (Virtual) Transcript
Great. Thanks, everyone, for continuing to join us on our second day of the inaugural Stifel Targeted Oncology Days. My name is Brad Canino, senior analyst here at Stifel. I'm happy to continue the fireside chat session with C4 Therapeutics. And I've got with me Andrew Hirsch, President and CEO; and Stew Fischer, Chief Scientific Officer. So, thank you both for joining me and sitting down for a conversation.
Great. Thanks, Brad, for having us.
Thanks, Brad.
Questions & Answers
So we're going to jump right into trying to cover all of the assets, which might be an impossible feat. But we're going to do our best. On the lead asset, CFT7455 or IKZF1 and IKZF3 degrader -- just open with current comments and what you can share about the status of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
